Michor completed her doctoral research in less than three years, after which she was made a Junior Fellow in the Harvard Society of Fellows.[3] Her early work considered the development of a mathematical model to study the evolution of cells that lead to the end stage of chronic myelogenous leukemia.[4] Specifically, Michor sought to understand why certain patients failed to improve after treatment with Gleevec.[3][5] Michor was the first researcher to be honoured with the Austrian Scientists and Scholars in North America (ASciNA) award.[4]